0. Advocacy Graphic


  • January 9, 2018

    State Policy Trends Affecting Treatment of Addiction Involving Opioid Use

    The opioid epidemic continued throughout the United States in 2017. State legislatures have remained engaged on this issue, with every state enacting some type of measure supporting prevention, treatment, or recovery in the past two years.
  • January 8, 2018

    ASAM Welcomes CDC Letter Clarifying Dosage Thresholds

    Several weeks ago, ASAM contacted the CDC to discuss the persistence of misunderstandings surrounding dosage thresholds in the CDC Guidelines for Prescribing Opioids for Chronic Pain – 2016 (Guideline) and addiction medicine.
  • December 6, 2017

    ASAM Applauds FDA's Approval of New Monthly Injectable Buprenorphine Formulation

    On December 30, 2017, the Food and Drug Administration (FDA) announced the approval of Sublocade, a monthly formulation of buprenorphine subcutaneous injection for treatment of opioid dependence. This injection is the first monthly formulation of buprenorphine to be approved by the FDA.
  • November 30, 2017

    New Parity@10 Compliance Campaign will Shine Important Light on Patients’ Treatment Needs

    When a patient seeks mental health care or treatment for a substance use disorder, the law makes clear that health insurers and regulators have legal obligations to ensure patients’ access to non-discriminatory care. We are very pleased that the Parity@10 Compliance Campaign will be taking an in-depth look at the significant challenges and barriers to care patients face when seeking treatment.
  • November 20, 2017

    ASAM Comments on the New Direction for the Centers for Medicare and Medicaid Innovation

    ASAM responds to a Request For Information (RFI) released by the Centers for Medicare and Medicaid Services (CMS) regarding their new direction for innovation.
  • November 17, 2017

    ASAM Cosigns Letter Opposing the Repeal of the ACA's Individual Mandate as a Part of Tax Reform

    On behalf of the Mental Health Liaison Group (MHLG), we are writing to express our opposition of specific provisions within the House and Senate versions of the Tax Cuts and Jobs Act, particularly the provisions repealing the Affordable Care Act’s individual shared responsibility mandate and the House’s provision repealing the medical expense deduction. 
  • November 14, 2017

    ASAM Joins Letter to Expand CBHC Demonstration Program

    The Mental Health Liaison Group is writing to express support the Excellence in Mental Health and Addiction Treatment Expansion Act (S. 1950/H.R.3931) -  legislation to expand the Certified Community Behavioral Health Center (CCBHC) demonstration program authorized in Section 223 of the Protecting Access to Medicare Act that is based on your Excellence in Mental Health Act.
  • November 6, 2017

    ASAM Welcomes New CMS Direction on Section 1115 Waivers

    ASAM commends CMS for issuing this new guidance which expands access to care and requires states to align their section 1115(a) demonstrations with certain goals and milestones.